Plasma Neurofilament Light and Phosphorylated Tau 181 as Biomarkers of Alzheimer's Disease Pathology and Clinical Disease Progression

Christopher Clark (christopher.clark@irem.uzh.ch)
Universitat Zurich

Piotr Lewczuk
Universitätsklinikum Erlangen

Johannes Komhuber
Universitätsklinikum Erlangen

Jonas Richiardi
University of Lausanne: Universite de Lausanne

Bénédicte Maréchal
University of Lausanne: Universite de Lausanne

Thomas K Karikari
University of Gothenburg: Goteborgs Universitet

Kaj Blennow
University of Gothenburg: Goteborgs Universitet

Henrik Zetterberg
University of Gothenburg: Goteborgs Universitet

Julius Popp
University Hospital of Psychiatry Zurich

Research

Keywords: Biomarkers, plasma, Alzheimer's, neurofilament light, p-tau181

DOI: https://doi.org/10.21203/rs.3.rs-135649/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: To assess the performance of plasma neurofilament light (NfL) and phosphorylated tau 181 (p-tau181) to inform about cerebral Alzheimer’s disease (AD) pathology and predict clinical progression in a memory clinic setting.

Methods: Plasma NfL and p-tau181, along with established cerebrospinal fluid (CSF) biomarkers of AD pathology (CSF β-amyloid 1-42 (Aβ1-42), Aβ1-42 / Aβ1-40, total-tau (tau), and p-tau181) were measured in participants with normal cognition (CN, n=91) and memory clinic patients with cognitive impairment (mild cognitive impairment and dementia, CI, n=127). Clinical and neuropsychological evaluations were performed at inclusion and follow-up visits at 18 and 36 months, to measure decline in global cognition and progression of disease severity. Multivariate analysis assessed associations of plasma NfL and p-tau181 levels with the presence of cerebral AD pathology (a priori defined by a CSF p-tau181/Aβ1-42 > 0.0779), single CSF biomarkers, and clinical measures of disease progression.

Results: Plasma NfL levels were higher in CN participants with an AD CSF profile, and in CI participants when compared to CN non-AD participants, while p-tau181 plasma levels were higher in CI patients with AD when compared to the other participants. Plasma NfL levels correlated with CSF tau and p-tau181 in CN, and with CSF tau in CI patients. Plasma p-tau181 correlated with CSF p-tau181 in CN and with CSF biomarkers in CI participants. Compared to a reference model, adding plasma p-tau181 improved the prediction of AD in CI patients (AUC 0.861, p-value = 0.048) while adding NfL did not. Adding p-tau181, but not NfL levels, to a reference model improved prediction of cognitive decline in CI participants (AUC 0.838, p-value = 0.032). Using a plasma p-tau181 cutoff of 9.68 pg/ml the models reached a sensitivity of 0.80 and specificity of 0.79 for AD prediction, and of 0.88 and 0.69 for the prediction of cognitive decline.

Conclusion: Plasma NfL may be useful as a marker of neuronal injury, although it is not specific for AD. P-tau181 can serve, in a memory clinic setting, as a blood-based biomarker of both cerebral AD pathology and cognitive decline. The predictive performance of both markers depends on the presence of cognitive impairment.

Background:

In vivo detection of the cerebral pathophysiological processes of Alzheimer’s disease (AD) is key to accurate diagnosis and appropriate care. Cerebrospinal fluid (CSF) and positron tomography biomarkers of amyloid and tau accurately detect AD, but are of limited use in clinical practice due to the associated costs, invasiveness, or non-availability of the tools needed (1). Non-invasive blood-based biomarkers could provide an attractive alternative, allowing to identify patients that may benefit from further, more invasive and/or costly diagnosis, or for recruitment and monitoring of participants in clinical trials (2).

Neurofilament light (NfL) protein and tau phosphorylated at threonine 181 (p-tau181) are promising candidates for blood-based biomarkers of AD. NfL blood level has been proposed as a biomarker for
axonal damage and neuronal injury (2), and has been found to be increased in clinically diagnosed AD compared to healthy controls (3–6). It also has been associated with cognitive decline in participants with normal cognition (7), and neurodegeneration across neurodegenerative diseases (8). Plasma p-tau181 has been recently reported to be increased in both clinically diagnosed (9) and biomarker confirmed AD dementia (10), and to correlate with CSF tau levels and amyloid PET measurements (11, 12). Furthermore, it may predict disease progression and cognitive decline in cognitively unimpaired participants and MCI patients (13).

Here, our aim was to test the ability of plasma NfL and plasma p-tau181 levels, or the combination thereof, to serve as blood-based biomarkers for the diagnosis of cerebral AD pathology and the prediction of clinical disease progression.

**Materials And Methods:**

**Study population**

Two hundred and twenty-one individuals aged 49 to 88 years were recruited at the memory clinic of the Department of Psychiatry and the Department of Clinical Neurosciences at the University Hospital of Lausanne, Switzerland into an AD biomarker discovery study cohort between 2014 and 2018. Participants were recruited among memory clinic patients and through advertising and word-of-mouth for healthy participants. All participants underwent a comprehensive clinical evaluation and neuropsychological assessment as previously described (14). Briefly, a comprehensive test battery along with standard questionnaires were used to determine the Clinical Dementia Rating (CDR; (15)), CDR sum of boxes (CDRSoB), Mini-mental state (MMSE), and to verify subgroup inclusion criteria. The cognitive impairment group (CI) included patients with the clinical diagnoses of mild cognitive impairment (MCI; (16)) or dementia, and a CDR score ≥ 0.5 (14). Patients with major psychiatric or neurological disorders, substance abuse or severe, or unstable physical illness that could affect cognition were excluded. Cognitively normal participants (CN) were free of relevant acute psychiatric or neurologic affection, had neither current cognitive impairment nor a history of it, and had a CDR = 0. MRI and CT scans were performed in all participants and used to exclude individuals with major cerebral pathologies possibly interfering with the cognitive performance. Clinical and neuropsychological evaluations were repeated after roughly 18 and 36 months, during follow-up visits using the same study protocol.

**Blood and cerebrospinal fluid collection**

Venous and lumbar punctures were performed after an overnight fast. Ten to twelve mL of CSF was collected for analyzing, centrifuged at 4 C, immediately aliquoted, and frozen at -80 C until assayed, as previously described (17).

**CSF AD biomarkers, albumin quotient, and Apolipoprotein E genotype**
CSF β-amyloid 1–42 peptide (Aβ1−42), total-tau (tau) and tau phosphorylated at threonine 181 (p-tau181) concentrations were measured using commercially available ELISA kits (Fujirebio Europe, Gent, Belgium). Additionally, the concentrations of Aβ1−42 and Aβ1−40 were measured with immunoassays from IBL International (Hamburg, Germany) according to the manufacturer’s protocols. The albumin CSF/serum quotient (QAlb) as a marker of blood-CSF barrier function along with the apolipoprotein E (APOE) genotype were determined as previously described (18).

**Plasma biomarkers**

NfL concentrations were measured using the NFLIGHT kit on a Single molecule array (Simoa) HD-X Analyzer (Quanterix, Billerica, MA, USA), following the recommendations by the manufacturer. Plasma p-tau181 levels were measured using an in house Simoa assay as previously described (10). Briefly, an AT270 mouse monoclonal antibody (MN1050; Invitrogen, Waltham, MA, USA) was coupled to paramagnetic beads (103207; Quanterix) and used for capture. As the detector, we used the anti-tau mouse monoclonal antibody Tau12 (806502; BioLegend, San Diego, CA, USA), conjugated to biotin (A3959; Thermo Fisher Scientific, Waltham, MA, USA), while GSK-3β phosphorylated full-length recombinant tau441 (TO8−50FN; SignalChem, Vancouver, BC, Canada) was used as calibrator. Fluorescent signals were converted to average enzyme per bead numbers as described (19), and specimen concentrations extrapolated from four-parametric logistic curves generated with known calibrator concentrations.

**Hippocampal volume measurements**

All participants underwent a magnetic resonance imaging scan at inclusion on a 3T MRI system (MAGNETOM Prismafit, Siemens Healthcare, Erlangen, Germany) with a 32-channel head coil. Acquisitions followed the ADNI2 MRI protocol (http://adni.loni.usc.edu/methods/documents/). Images were segmented with the MorphoBox prototype (20), and both overall image (21) and segmentation quality were automatically assessed (20). Here we used regional volumetric data normalized by total intracranial volume (defined as the sum of gray matter, white matter and CSF) to determine relative hippocampal volume.

**Data and statistical analysis**

Before analysis, outliers for CSF and plasma biomarker levels (i.e. data points that exceeded the cut-off value of mean ± 3 × SD, accounting for less than 3% of data points) were replaced by the cut-off value to minimize quantification errors. All participants within the CN and CI subgroups were further classified as AD or non-AD according to the presence or absence of an AD CSF profile. An AD CSF profile was defined by a CSF p-tau181/Aβ1−42 ratio > 0.0779 based on center data and in line with previous publications (22), as previously described (17). Biomarker and cognitive change data were logn-transformed prior to correlation and regression analyses to approach Gaussian distribution. Subgroups within the cohort were compared using Students’ two-tailed t-test for continuous variables and Chi-square tests for categorical variables. Data are given as mean ± standard-deviation. Correlations between CSF AD biomarkers and plasma biomarkers were assessed using Spearman’s rho. Benjamini-Hochberg correction of P-value for
multiple testing was applied for all analyses using a false-discovery rate of 0.1. Potential collinearity of the explanatory variables used in the regression modelling was tested with variance inflation factor (VIF). No variable entered in these models had VIF above 1.5, thus absence of multicollinearity was assumed. Statistical data analysis was performed with IBM SPSS Statistics software version 25.

**Statistical modelling**

To assess the association of plasma NfL and plasma p-tau181 with the presence of AD pathology, we used logistic regression models with occurrence of AD as dependent variable while entering both plasma markers as independent variables. We explored the effects of the following covariates: age, sex, years of education and \( APOE \varepsilon4 \) status. Best predictive models were obtained using a backwards selection method where variables with a likelihood-ratio statistic probability > 0.1 were removed iteratively. A reference model for prediction of AD using only age, sex, years of education and with or without \( APOE \varepsilon4 \) status was constructed using logistic regression in the CN and CI subgroups individually. We then added either plasma NfL levels or plasma p-tau181 levels, or both to this model. Predictive performance was assessed by computing a ROC curve and area under the curve (AUC) for these models and were compared using the DeLong method. Estimation of cut points for p-tau181 for the prediction of a CSF AD profile was done using R software (cutpointr package) and selecting the cut-off level that maximized the prediction accuracy of logistic regression models in CI participants.

Associations of plasma NfL and plasma p-tau181 with cognitive measurement changes were first assessed with linear regression models using CDRSoB or MMSE changes at last follow-up visit as a dependent variable while entering both plasma markers as independent variables. We explored the effects of the following covariates: age, sex, years of education and \( APOE \varepsilon4 \) status, and baseline MMSE or CDRSoB scores, and time to follow-up. Best predictive models were obtained using a backwards selection method, where variables with a F-score statistic probability > 0.1 and the smallest correlation with the dependent variables were removed iteratively. In parallel, reference models for the prediction of clinical disease progression (CDRSoB change \( \geq 1 \)) or decline in global cognition (MMSE change \( \geq -2 \)) using the above covariates were constructed in the CN and CI subgroups separately. We then added either plasma NfL levels or plasma p-tau181 levels, or both, to these models. Predictive performance was assessed using ROC and AUC values of models compared using the DeLong method as above.

Goodness-of-fit of logistic regression models was assessed using the Hosmer-Lemeshow test. None of the above models displayed a Hosmer-Lemeshow chi-squared value yielding a P-value < 0.05 and therefore none were rejected.

**Data availability**

The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

**Results:**
Cohort description

Subject characteristics and cognitive assessments average by group comparisons, based on cognitive status at baseline together with AD CSF biomarkers, biochemical measures, and plasma NfL and p-tau181 levels, are shown in Table 1. Longitudinal clinical data from at least one FU visit after 36.68 ± 16.67 months in CN participants (n = 79) and 33.9 ± 16.07 months in CI (n = 94, p-value = 0.256) showed CDRSoB changes of 0.241 ± 0.76 and 2.88 ± 3.62 in CN and CI participants respectively (p-value < 0.001). For MMSE we observed a change of -0.17 ± 1.16 in CN participants and of -3.15 ± 5.60 in CI patients (p-value < 0.001). In CN participants both plasma NfL and p-tau181 levels positively correlated with age (spearman's rho = 0.602 and 0.249, respectively), while in CI patients plasma NfL correlated with age and years of education (rho = 0.363 and − 0.243 respectively) and p-tau181 with APOE ε4 status (rho = 0.223). Neither plasma NfL nor plasma p-tau181 correlated with Qalb. Furthermore, NfL levels correlated with CDR, CDRSoB and MMSE scores (rho = 0.307, 0.44 and − 0.295 respectively) in CI patients.
Table 1
Characteristics of the study cohort

|                                      | CN (n = 91) | CI (n = 127) | p-value |
|--------------------------------------|-------------|--------------|---------|
| **Demographic and clinical characteristics** |             |              |         |
| Sex, Female (%)                      | 64.4        | 53.9         | 0.12    |
| Age (years), mean ± SD               | 68.53 ± 7.31| 74 ± 6.6     | < 0.001 |
| Years of education (years), mean ± SD| 13.02 ± 2.54| 12.26 ± 2.78 | 0.04    |
| CDR, mean ± SD                       | 0           | 0.59 ± 0.26  | < 0.001 |
| CDRSoB, mean ± SD                    | 0.01 ± 0.07 | 2.12 ± 2.14  | < 0.001 |
| MMSE, mean ± SD                      | 28.59 ± 1.25| 25.29 ± 3.83 | < 0.001 |
| **Biochemical measures**             |             |              |         |
| APOE ε4, n (%)                       | 18 (21.2)   | 50 (43.5)    | 0.001   |
| QA1b, mean ± SD                      | 5.45 ± 2.28 | 6.93 ± 3     | 0.002   |
| **CSF AD biomarkers**                |             |              | < 0.001 |
| Aβ1−42, pg/ml, mean ± SD             | 1030.62 ± 262.46 | 754.58 ± 287.32 | < 0.001 |
| Tau, pg/ml, mean ± SD                | 301.09 ± 175.95 | 493.04 ± 308.79 | < 0.001 |
| p-tau181, pg/ml, mean ± SD           | 57.74 ± 20.48 | 70.49 ± 29.77 | < 0.001 |
| Aβ1−42/Aβ1−40                        | 0.07 ± 0.02  | 0.05 ± 0.02  | < 0.001 |
| **MRI**                              |             |              |         |
| Hippocampal volume                   | 0.0046 ± 46E-5 | 0.0041 ± 57E-5 | < 0.001 |
| **Plasma biomarkers**                |             |              |         |
| NfL, pg/ml, mean ± SD                | 17.61 ± 9.24 | 24.66 ± 11.66 | < 0.001 |
| p-tau181, pg/ml, mean ± SD           | 9.58 ± 7.09  | 14.78 ± 9.69 | < 0.001 |

**Associations of plasma NfL and p-tau181 levels with AD**

Plasma NfL levels were significantly higher in CN participants with cerebral AD pathology (as indicated by the presence of an AD CSF profile) and in both AD and non-AD CI patients when compared to CN non-AD participants (Fig. 1A). Plasma p-tau181 levels were significantly increased in CI participants with AD as compared to CI non-AD patients and both AD and non-AD CN participants (Fig. 1B). Hippocampal volume did not show significant differences between AD and non-AD subgroups in either CN or CI.
participants (data not shown). When considering the following covariates in a regression model, age, sex, years of education and *APOE* ε4 status only p-tau181 levels remained associated with AD in CI participants (Fig. 2A). Applying backwards variable selection to both of these models identified age for CN participants and age, *APOE* ε4 status and p-tau181 levels in CI participants as independent predictors of AD (Fig. 2B). The addition of plasma p-tau181 levels to a reference model to predict the presence of AD pathology, improved prediction accuracy in CI participants (Fig. 2C, D, p-value = 0.048; sensitivity: 0.8; specificity: 0.79). Using a plasma p-tau181 cut-off at 9.68 pg/ml improved the prediction of AD (AUC = 0.869, p-value = 0.036) in CI participants. Using this cut-off also improved the prediction of AD in the whole cohort (AUC = 0.861, p-value = 0.012). Plasma NfL levels did not contribute to improving the prediction of AD (Fig. 2D), nor did adding both markers in combination (data not shown).

**Associations of plasma NfL and p-tau181 with CSF biomarkers of amyloid pathology, neuronal injury, and tau hyperphosphorylation**

In the whole cohort, both plasma NfL and p-tau181 levels correlated with all assessed AD CSF biomarkers and with the hippocampal volume. In CN participants, plasma NfL levels correlated with those of CSF tau and p-tau181 and plasma p-tau181 correlated with CSF p-tau181. In CI participants, plasma NfL levels correlated with CSF tau and hippocampal volume whereas plasma p-tau181 levels were correlated with all AD CSF biomarkers but not hippocampal volume (Table 2).
Table 2
Correlations (rho) between plasma NfL and plasma p-tau181 levels with CSF biomarkers of AD.

|                          | Plasma NfL |            | Plasma p-tau181 |            |
|--------------------------|------------|------------|-----------------|------------|
|                          | rho        | p-value    | rho             | p-value    |
| **Whole cohort**         |            |            |                 |            |
| CSF Aβ1-42               | -0.173     | 0.015      | -0.383          | <0.001     |
| CSF Aβ1-42/Αβ1-40        | -0.18       | 0.012      | -0.356          | <0.001     |
| CSF p-tau181             | 0.309       | <0.001     | 0.424           | <0.001     |
| CSF tau                  | 0.389       | <0.001     | 0.428           | <0.001     |
| Hippocampal volume       | -0.315      | <0.001     | -0.215          | 0.008      |
| **CN participants**      |            |            |                 |            |
| CSF Aβ1-42               | 0.130       | 0.235      | -0.021          | 0.849      |
| CSF Aβ1-42/Αβ1-40        | -0.074      | 0.510      | -0.0173         | 0.128      |
| CSF p-tau181             | 0.242       | 0.026      | 0.326           | 0.003      |
| CSF tau                  | 0.26        | 0.016      | 0.213           | 0.055      |
| Hippocampal volume       | 0.027       | 0.817      | 0.023           | 0.849      |
| **CI participants**      |            |            |                 |            |
| CSF Aβ1-42               | -0.052      | 0.584      | 0.415           | <0.001     |
| CSF Aβ1-42/Αβ1-40        | -0.006      | 0.950      | -0.328          | <0.001     |
| CSF p-tau181             | 0.148       | 0.116      | 0.417           | <0.001     |
| CSF tau                  | 0.233       | 0.013      | 0.496           | <0.001     |
| Hippocampal volume       | -0.349      | 0.002      | -0.135          | 0.235      |

**Associations of plasma NfL and p-tau181 with disease severity progression and cognitive decline**

In CN participants, only NfL plasma levels were associated with changes in CDRSoB, while in the CI group NfL levels were associated with changes in CDRSoB and p-tau181 levels were associated with changes in both CDRSoB and MMSE (Table 3). After controlling for age, sex, years of education, APOE ε4 status,
baseline score, and time to follow-up; the association of plasma NfL levels with CDRSoB changes remained significant in CN participants, as well as the association of p-tau181 with MMSE change in CI participants (Fig. 3A). Applying backwards selection to determine the best predictive models identified plasma NfL as an independent predictor of changes in CDRSoB in CN participants; and plasma p-tau181 as an independent predictor of MMSE changes in CI participants (Fig. 3B). Adding plasma p-tau181 levels to a reference model improved the prediction of decline in global cognition in CI participants (Fig. 3C, D, p-value = 0.0318; sensitivity: 0.88; specificity: 0.69). Despite their association with CDRSoB changes, plasma NfL levels did not contribute to improve prediction of disease severity progression when compared to a reference model (data not shown). Combinations of both plasma markers did not improve this prediction either (data not shown).

Table 3:
Associations of plasma NfL and p-tau181 levels with CDRSoB and MMSE change

|            | ΔCDRSoB |         |         | ΔMMSE |         |         |
|------------|---------|---------|---------|-------|---------|---------|
|            | Variable | Coeff.  | p-value | Variable | Coeff.  | p-value |
| CN         | NfL     | 0.386   | 0.001   | NfL    | -0.142  | 0.240   |
|            | p-tau181| -0.056  | 0.620   | p-tau181| 0.030   | 0.801   |
| CI         | NfL     | 0.227   | 0.035   | NfL    | -0.145  | 0.230   |
|            | p-tau181| 0.252   | 0.020   | p-tau181| -0.293  | 0.017   |

Table 3: Linear regression models with changes in CDRSoB (ΔCDRSoB) or MMSE (ΔMMSE) at last follow-up as dependent variables with plasma NfL of p-tau181 levels. For each variable, standardized coefficients (Coeff.) and significance are shown.

Discussion:

Plasma NfL levels were higher in CN participants with AD CSF biomarker profile as compared to CN with non-AD biomarker profile while plasma p-tau181 levels were higher in the CI patients with AD CSF profile. Plasma levels beyond 9.68 pg/ml were associated with higher occurrence of AD and adding them to a reference model improved the prediction of AD in CI participants. Plasma NfL levels were associated with CDRSoB changes over time in CN and CI patients while plasma p-tau181 levels were associated with changes in both CDRSoB and MMSE in CI. Adding plasma p-tau181 levels to a reference model improved the predictive performance of decline in global cognition in CI participants.

Both plasma biomarkers were associated with the presence of cerebral AD pathology as defined by a high CSF p-tau181/Aβ1–42 ratio. Previous studies have reported higher plasma NfL levels to be associated with AD dementia (3, 5, 4, 6). These studies defined AD using clinical assessment only (23) and did not consider CSF biomarkers for AD diagnosis. Accordingly, patients presenting clinically as AD
dementia, but having cognitive impairment due to other cerebral pathologies may have been misdiagnosed and included, whereas our approach considers cerebral pathology as measured by CSF biomarkers. Additionally, we considered in our reference model known diagnosis covariates, including \textit{APOE} $\varepsilon$4 status. We found that while plasma NfL is associated with AD it does not have an independent effect on the prediction of AD when considering covariates. These results along with the correlations between NfL and CSF tau, but not CSF A$\beta$1--42 and CSF A$\beta$42/A$\beta$40 ratio reinforce the role of NfL as a marker for neuronal injury (2), although not in an AD specific fashion as, in line with previous work, NfL appears independent of amyloid pathology (24).

Previous studies found associations of elevated plasma p-tau181 with amyloid positivity in participants with normal cognition or with cognitive impairment $^{8,12,11}$. A study found that combining plasma p-tau181 levels with either CSF tau or p-tau181 increases the predictive performance of clinically defined AD (25). Another study that defined AD considering both amyloid pathology and tau pathology reported results in line to ours, i.e. elevated p-tau181 levels in AD and predictive power in MCI and dementia participants (10). The addition of plasma p-tau181 levels to a reference model including age, sex, years of education and \textit{APOE} $\varepsilon$4 status significantly improved the prediction performance for AD in CI patients. We observed a significant contribution of plasma p-tau181 independently of \textit{APOE} $\varepsilon$4 in this model.

Previous studies investigating the association of plasma p-tau181 with AD, either did not consider the \textit{APOE} genotype ($^{13,12}$); or they did not consider the effects of this factor independently of p-tau181 ($^{10,9}$). Considering the \textit{APOE} $\varepsilon$4 genotype as a covariate, we found that plasma p-tau181 additionally contributes to improve the prediction of AD in patients with cognitive impairment. This finding suggests that combining \textit{APOE} $\varepsilon$4 genotype and plasma p-tau181 with clinical variables is superior to considering \textit{APOE} $\varepsilon$4 genotype alone for the diagnosis of AD in memory clinic patients with cognitive impairment.

Together, our results indicate that plasma NfL levels can be used to identify participants with normal cognition at increased risk of having cerebral AD pathology, and contributes to identifying neurodegeneration irrespective of the underlying cause. However, plasma NfL does not seem suitable to improve differential diagnosis of AD in memory clinic patients with cognitive impairment. On the other hand, plasma p-tau181 levels have an independent and significant contribution to the prediction of the presence of cerebral AD pathology and appear to be more specific than plasma NfL levels for AD pathology. Therefore, plasma p-tau181 may be more appropriate for differential diagnosis in memory clinic patients presenting with cognitive impairment.

The non-specificity of the association of plasma NfL with AD is further shown by correlations of plasma NfL with CSF tau levels, independently of cognitive status, while only a weak correlation with CSF p-tau181 in CN, and no correlation with CSF markers other than CSF tau were present in CI. In a previous study, plasma NfL was not associated with any CSF biomarker in CN participants and AD dementia patients, but in MCI participants it was associated with CSF A$\beta$1--42 and CSF tau (3). Plasma NfL levels have been previously correlated to amyloid load assessed by PET scan in cognitively normal participants (26). This suggests AD pathology might be the main cause of neuronal injury and therefore NfL increase in CN participants, while in a majority of patients in the CI group neuronal injury might be caused by other
pathologies, rendering NfL inefficient for differential diagnosis in this later group. Conversely, plasma p-tau181 levels correlated with CSF p-tau181 in CN participants and with all CSF biomarkers in CI participants, reinforcing its role as a biomarker candidate useful for differential diagnosis of AD.

In both CN and CI groups, higher plasma NfL baseline levels were associated with more rapid increase in disease severity as indicated by CDRSoB change at follow-up. After controlling for possible confounders only the association of plasma NfL levels with CDRSoB changes in CN participants remained significant. Previous studies have reported plasma NfL levels to correlate with baseline cognition (7, 4–6, 3). Of these studies, only two considered both CDR and MMSE scores (7, 4), and a single study reported a correlation of plasma NfL levels with longitudinal MMSE change in cognitively impaired participants (3). In line with previous reports (6, 4, 5), in CI patients higher NfL was associated with more marked increase in clinical disease severity over time. When added to a reference model based on clinical variables and the APOE ε4 status, plasma NfL did not significantly improve the prediction of severity progression at follow-up visit, however. Since NfL can be associated with neuronal injury of multiple aetiologies rather than with a specific pathological mechanism, elevated levels are indicative of multiple potential outcomes, rendering it inappropriate for modelling. Overall, our results suggest plasma NfL may be useful as a blood-based marker to identify individuals at high risk of cognitive decline among cognitively normal individuals.

We found higher plasma p-tau181 levels to be associated with more rapid increase in disease severity as well as with more marked decline in global cognition as assessed by changes in MMSE. Adding plasma p-tau181 levels to a reference model including age, sex, years of education, APOE ε4 status, baseline MMSE, and time to follow-up, significantly improved the prediction of decline in global cognition in CI participants. While the association of high levels of plasma p-tau181 with cognitive decline has been previously observed in MCI patients (13), we show here the added value of this plasma marker to predict cognitive decline when combined with other non-invasive measures. While these findings remain to be confirmed in an independent cohort, they suggest the utility of plasma p-tau181 in clinical practice as a blood-based prognostic biomarker for cognitive decline, in particular in patients with cognitive impairment.

Limitations:

A limitation of this study is the relatively small number of included participants with dementia, preventing us to specifically address the performance of the plasma biomarker candidates in this subgroup. Our work does however benefit from the inclusion of both elderly participants with normal cognition and memory clinic patients with cognitive impairment, allowing the assessment of differential diagnosis utility. Furthermore, we used established CSF biomarkers of cerebral AD pathology to define AD at both the asymptomatic and the clinical stage, enabling to address relationships to cerebral pathology while ensuring cognitive impairment due to other cerebral pathologies was not misdiagnosed as AD. Additionally, we have considered multiple covariates in this study, therefore assessing the specific clinical relevance of plasma NfL and p-tau181 levels. Confirmation in independent samples and memory clinics is needed before applying the findings in clinical practice, however.
Conclusions:

We have investigated the associations of plasma NfL and p-tau181 levels with CSF biomarkers of amyloid, neuronal injury, and tau pathology, and the predictive performance of the plasma marker candidates for cerebral AD pathology and cognitive decline. Our results suggest that plasma NfL may be useful as a blood-based marker to identify cognitively normal individuals at risk of cognitive decline. Plasma p-tau181 levels can serve as a predictive blood-based biomarker of both AD pathology and cognitive decline, but its performances depend on whether it is used in cognitively normal older individuals or in patients with cognitive impairment. While these findings need further validation before use in clinical practice, they show the potential utility of blood-based biomarkers in both older individuals with normal cognition and memory clinic patients with cognitive impairment.

List Of Abbreviations:

\( \text{A}^\beta_{1-42} \) CSF \( \beta \)-amyloid 1-42 peptide

AD Alzheimer’s disease

APOE apolipoprotein E

AUC Area under the curve

CDR Clinical dementia rating

CDRSoB CDR sum of boxes

CSF Cerebrospinal fluid

CN Normal cognition group

CI Cognitive impairment group

MCI Mild cognitive impairment

MMSE Mini-mental state

NfL Neurofilament light

p-tau181 Tau phosphorylated at threonine 181

QAlb albumin CSF/serum quotient

tau total-tau

VIF variance inflation factor
Declarations:

**Ethics approval and consent to participate**

The study was conducted in accordance with applicable laws and regulations, the local ethics committee approved this study (No. 171/2013), and all participants or their legal representatives provided written informed consent.

**Consent for publication**

Not applicable

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

PL received consultation and/or lecture honoraria from IBL International, Fujirebio Europe, AJ Roboscreen, and Roche. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). JR owns shares in Siemens healthcare. JP received consultation and speaker honoraria from Nestle Institute of Health Sciences, Innovation Campus, EPFL, Lausanne, Switzerland, Ono Pharma, OM Pharma Suisse and from Fujirebio Europe. The other authors declare no potential conflicts of interest.

**Funding**

This work was supported by grants from the Swiss National Research Foundation (to JP, SNF 320030_141179), Synapsis Foundation - Alzheimer Research Switzerland (to JP, grant number 2017-PI01)

**Authors’ contributions**

CC an JP designed the study and interpreted the data. CC performed statistical analysis and modelling. CC, PL and JP drafted the manuscript. PL, JK, TK, KB, HZ and JP contributed biomarkers measurements. JR and BM contributed MRI data. All authors reviewed the manuscript. The authors read and approved the final manuscript.
Acknowledgements

Not applicable

References:

1. Molinuevo JL, Ayton S, Batra R, Bednar MM, Bittner T, Cummings J et al. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol 2018; 136(6):821–53.

2. Hampel H, O’Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 2018; 14(11):639–52.

3. Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA neurology 2017; 74(5):557–66. Available from: URL: https://pubmed.ncbi.nlm.nih.gov/28346578/.

4. Lin Y-S, Lee W-J, Wang S-J, Fuh J-L. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep 2018; 8(1):17368.

5. Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Res Ther 2018; 10(1):71.

6. Zhou W, Zhang J, Ye F, Xu G, Su H, Su Y et al. Plasma neurofilament light chain levels in Alzheimer’s disease. Neurosci Lett 2017; 650:60–4.

7. Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA neurology 2019; 76(7):791–9.

8. Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. Journal of neurology, neurosurgery, and psychiatry 2019; 90(8):870–81. Available from: URL: https://pubmed.ncbi.nlm.nih.gov/30967444/.

9. Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ et al. Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement 2018; 14(8):989–97.

10. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. The Lancet Neurology 2020; 19(5):422–33.

11. Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med 2020; 26(3):387–97.

12. Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and
longitudinal progression to Alzheimer's dementia. Nat Med 2020; 26(3):379–86.

13. Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suárez-Calvet M et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Molecular Psychiatry 2020.

14. Mathys J, Gholamrezaee M, Henry H, Gunten A von, Popp J. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer’s pathology in MCI and mild dementia. Experimental gerontology 2017; 100:45–53. Available from: URL: https://pubmed.ncbi.nlm.nih.gov/29054536/.

15. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43(11):2412–4.

16. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L-O et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256(3):240–6.

17. Popp J, Oikonomidi A, Tautvydaite D, Dayon L, Bacher M, Migliavacca E et al. Markers of neuroinflammation associated with Alzheimer’s disease pathology in older adults. Brain Behav Immun 2017; 62:203–11.

18. Bowman GL, Dayon L, Kirkland R, Wojcik J, Peyratout G, Severin IC et al. Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimers Dement 2018; 14(12):1640–50.

19. Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010; 28(6):595–9.

20. Schmitter D, Roche A, Maréchal B, Ribes D, Abdulkadir A, Bach-Cuadra M et al. An evaluation of volume-based morphometry for prediction of mild cognitive impairment and Alzheimer’s disease. Neuroimage Clin 2015; 7:7–17.

21. Mortamet B, Bernstein MA, Jack CR, Gunter JL, Ward C, Britson PJ et al. Automatic quality assessment in structural brain magnetic resonance imaging. Magn Reson Med 2009; 62(2):365–72.

22. Duits FH, Teunissen CE, Bouwman FH, Visser P-J, Mattsson N, Zetterberg H et al. The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean? Alzheimers Dement 2014; 10(6):713-723.e2.

23. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7(3):263–9.

24. Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer’s disease. EMBO Mol Med 2016; 8(10):1184–96.

25. Fossati S, Ramos Cejudo J, Debure L, Pirraglia E, Sone JY, Li Y et al. Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer’s disease. Alzheimer’s & dementia (Amsterdam,
26. Benedet AL, Ashton NJ, Pascoal TA, Leuzy A, Mathotaarachchi S, Kang MS et al. Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals. Alzheimer's & dementia (Amsterdam, Netherlands) 2019; 11:679–89.